{"id":390866,"date":"2017-11-03T00:00:00","date_gmt":"2017-11-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2017-biopharma-psoriasis-disease-landscape-and-forecast-g7-2017\/"},"modified":"2026-06-25T23:40:09","modified_gmt":"2026-06-25T23:40:09","slug":"dlsfim0005-2017-biopharma-psoriasis-disease-landscape-and-forecast-g7-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2017-biopharma-psoriasis-disease-landscape-and-forecast-g7-2017\/","title":{"rendered":"Psoriasis | Disease Landscape and Forecast | G7 | 2017"},"content":{"rendered":"<p>The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>)-alpha inhibitors and interleukin (<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>)-12 and -23 inhibitor ustekinumab (Janssen\u2019s Stelara) is being challenged by the introduction of the highly effective\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitors. In particular, the uptake of secukinumab (Novartis\u2019s\u00a0Cosentyx) has been remarkable in the first two years of its launch, but the agent faces competition from the newer\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitors\u2014ixekizumab (Eli Lilly\u2019s Taltz) and brodalumab (Valeant\/LEO\u00a0Pharma\/Kyowa Hakko Kirin\u2019s Siliq\/Kyntheum\/Lumicef). With the approval and launch of Janssen\u2019s\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-23 inhibitor,\u00a0guselkumab\u00a0(Tremfya), another effective drug class has been introduced to the increasingly competitive market. Additionally, the landscape for the established biologics will change further with the increasing availability and usage of biosimilars.<\/p>\n<ul>\n<li><strong>How do interviewed\u00a0<abbr data-original-title=\"key opinion leader\" title=\"\">KOL<\/abbr>s view the efficacy and safety of the\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-17 inhibitors (Cosentyx, Taltz, Siliq\/Lumicef), and where are\/will these agents be positioned in the psoriasis treatment algorithm?<\/strong><\/li>\n<li><strong>What will be the impact of the\u00a0<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>-23 inhibitors (guselkumab, Merck &#038; Co.\/Almirall\/Sun Pharma\u2019s tildrakizumab, AbbVie\/Boehringer Ingelheim\u2019s risankizumab), and how will they fare in the competitive psoriasis market?<\/strong><\/li>\n<li><strong>How is the oral agent apremilast (Celgene\u2019s Otezla) used for psoriasis treatment, and what are the other promising emerging oral therapies?<\/strong><\/li>\n<li><strong>How fast will the uptake of biosimilars occur in psoriasis, and which brands will have\u00a0the greatest erosion in patient shares and sales?<\/strong><\/li>\n<\/ul>\n<p><strong>Scope:<\/strong><\/p>\n<p><b>Markets covered:<\/b>\u00a0United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><b>Primary research:<\/b>\u00a037\u00a0country-specific interviews with thought leaders.<\/p>\n<p><b>Epidemiology:<\/b>\u00a0Number of total, diagnosed, and drug-treated prevalent cases of psoriasis; number of diagnosed prevalent cases of psoriasis by severity.<\/p>\n<p><b>Emerging therapies:<\/b>\u00a0Phase II: 11\u00a0drugs; Phase III\/preregistration: 7\u00a0drugs; coverage of select preclinical and Phase I products.<\/p>\n","protected":false},"template":"","class_list":["post-390866","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}